Dergiler / Turkish Thoracic Journal / 2020 / Cilt: 21 - Sayı: 2

Newborn Screening for Cystic Fibrosis in Mersin Province: Yearly Assessment of the National Program

Sayfa
100–104
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The positive predictive value of IRT test fordefiing CF was 1.8%, with a sensitivity of 90.0% and specifiity of 99.4%.CONCLUSION: IRT/IRT test as a newborn screening strategy provides the opportunity for earlier diagnosis and treatment of CF patients.More data are needed to understand the frequency of CF on a national level.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVES: A national newborn screening program for cystic firosis (CF) was started using immunoreactive trypsinogen (IRT) test onJanuary 1, 2015, in Turkey.
📊
Temel Bulgular & Veri:We aimed to analyze the characteristics of newborn screen-positive (NBSP) infants in Mersin province.MATERIALS AND METHODS: The data on NBSP infants were retrospectively analyzed between 2015 and 2017 from records of MersinWomen & Children's Hospital and Mersin City Training and Research Hospital.RESULTS: A total of 82,273 newborns were screened for CF by IRT test between January 2015 and December 2017 in Mersin.
💡
Sonuç & Katkı:The positive predictive value of IRT test fordefiing CF was 1.8%, with a sensitivity of 90.0% and specifiity of 99.4%.CONCLUSION: IRT/IRT test as a newborn screening strategy provides the opportunity for earlier diagnosis and treatment of CF patients.More data are needed to understand the frequency of CF on a national level.
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVES: A national newborn screening program for cystic firosis (CF) was started using immunoreactive trypsinogen (IRT) test onJanuary 1, 2015, in Turkey. We aimed to analyze the characteristics of newborn screen-positive (NBSP) infants in Mersin province.MATERIALS AND METHODS: The data on NBSP infants were retrospectively analyzed between 2015 and 2017 from records of MersinWomen & Children's Hospital and Mersin City Training and Research Hospital.RESULTS: A total of 82,273 newborns were screened for CF by IRT test between January 2015 and December 2017 in Mersin. Amongthose, 512 infants were defied as NBSP after two repeated IRT tests (IRT/IRT) (138 infants in 2015, 217 in 2016, and 157 in 2017). Sweattest was normal in the majority of infants (115 infants [83.3%] in 2015, 189 [87.1%] in 2016, and 129 [82.2%] in 2017). Overall, between 2015 and 2017, after two repeated sweat tests, 4 infants had sweat test results in the intermediate range and 9 infants had positivesweat tests. The incidence of CF for a 3-year period was approximately 1/9300 in our region. The positive predictive value of IRT test fordefiing CF was 1.8%, with a sensitivity of 90.0% and specifiity of 99.4%.CONCLUSION: IRT/IRT test as a newborn screening strategy provides the opportunity for earlier diagnosis and treatment of CF patients.More data are needed to understand the frequency of CF on a national level.

🔖

Bu Makaleye Atıf Yap

ÖZDEMİR, A., DOĞRUEL, D. (2022). Newborn Screening for Cystic Fibrosis in Mersin Province: Yearly Assessment of the National Program. Turkish Thoracic Journal, Cilt: 21 - Sayı: 2, 100–104. https://ajindex.com/articles/618108

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Anselmo MA, Lands LC. Cystic firosis: overview. Taussig LM, Landau LIL, Le Souef PN, Morgan WJ, Martinez FD, Sly PD, editors. Pediatric Respiratory Medicine (2nd ed) Philadelphia: Mosby; 2008:845-57
  2. Tiddens H, Rosenfeld M. Cystic firosis: respiratory manifestations. Taussig LM, Landau LIL, Le Souef PN, Morgan WJ, Martinez FD, Sly PD, editors. Pediatric Respiratory Medicine (2nd ed). Philadelphia: Mosby; 2008: 871-87
  3. Zvereff VV, Faruki H, Edwards M, et al. Cystic firosis carrier screening in a North American population. Genet Med 2014;16:539-46. [CrossRef] 4. Kiper N. Kistik kibrozis; ülkemizdeki durum. J Curr Pediatr 2007:5
  4. Collins FS, Riordan JR, Tsui LC. The cystic firosis gene: isolation and signifiance. Hosp Pract (Off Ed) 1990;25:47-57. [CrossRef] 6. Sosnay PR, Raraigh KS, Gibson RL. Molecular genetics of cystic firosis transmembrane conductance regulator: genotype and phenotype. Pediatr Clin North Am 2016;63:585-98. [CrossRef] 7. Available from:
  5. Crossle JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic firosis in the newborn. Lancet 1979;1:472-4. [CrossRef] 9. Southern KW, Munck A, Pollitt R, et al. A survey of newborn screening for cystic firosis in Europe. J Cyst Fibros 2007;6:57- 65. [CrossRef] 10. Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic firosis. J Pediatr 2009;155:73-93. [CrossRef] 11. Tridello G, Castellani C, Meneghelli I, et al. Early diagnosis from newborn screening maximises survival in severe cystic firosis. ERJ Open Res 2018;4:00109-2017. [CrossRef] 12. Ersu R, Çakır E. Kistik firozis yenidoğan tarama testi ile tanı alan hastaları izleme rehberi. Ankara: T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu 2015:6
  6. Li L, Zhou Y, Bell CJ, et al. Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen. J Med Screen 2006;13:79-84. [CrossRef] 14. Machogu E, Ren CL. Novel insights into the diagnostic and therapeutic challenges of the CFTR metabolic syndrome/CF screen positive indeterminate diagnosis. Pediatr Pulmonol 2016;51:45- 8. [CrossRef] 15. Barben J, Southern KW. Cystic firosis screen positive, inconclusive diagnosis. Curr Opin Pulm Med 2016;22:617-22. [CrossRef] 16. Southern KW, Munck A, Pollitt R, et al. A survey of newborn screening for cystic firosis in Europe. J Cyst Fibros 2007;6:57-65